COGTCogent Biosciences, Inc.vs its industry peers
A metric-by-metric comparison of Cogent Biosciences, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COGTEsta | $5.7B#11 | — | 10.8x#9 | 727.7x#6 | -65.0%#7 | -28.6%#8 | -4235.3%#6 | -61.8%#13 | -84.3%#4 | — | 167.2%#8 | — |
| MRNA | $63.3B#1 | — | 9.4x#8 | 32.6x#2 | -39.9%#6 | 20.8%#5 | -158.1%#3 | -41.7%#11 | -54.6%#3 | — | 534.4%#4 | — |
| TWST | $9.9B#3 | — | 22.3x#13 | 26.3x#1 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#7 | -41.4%#2 | — | 486.3%#6 | — |
| ORKA | $6.3B#10 | — | 5.6x#3 | — | — | -25.9%#7 | — | -9.5%#4 | — | — | 487.7%#5 | — |
| KYMR | $9.9B#4 | — | 6.5x#6 | 251.8x#5 | -16.7%#5 | 39.1%#2 | -891.1%#5 | 20.6%#1 | — | — | 146.7%#10 | — |
| VKTX | $3.4B#14 | — | 8.4x#7 | — | — | -227.1%#15 | — | -88.1%#14 | — | — | 27.1%#14 | — |
| PRAX | $8.6B#7 | — | 6.4x#4 | — | -100.0%#9 | -65.6%#11 | — | -22.6%#9 | — | — | 598.5%#2 | — |
| ERAS | $5.3B#13 | — | 14.7x#10 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | 814.7%#1 | — |
| RVMD | $41.8B#2 | — | 16.0x#11 | — | — | -88.5%#13 | — | -43.4%#12 | — | — | 345.4%#7 | — |
| RYTM | $6.8B#8 | — | 66.4x#14 | 36.0x#3 | 45.8%#3 | 24.6%#3 | -101.2%#2 | -0.2%#3 | -133.8%#5 | — | 3.3%#15 | — |
| CGON | $6.7B#9 | — | 6.5x#5 | 1653.5x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#6 | -18.8%#1 | — | 99.9%#11 | — |
| SLS | $2.3B#15 | — | 17.0x#12 | — | -100.0%#9 | 13.0%#6 | — | -19.5%#8 | — | — | 582.0%#3 | — |
| PCVX | $9.0B#6 | — | 3.3x#1 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | 96.1%#12 | — |
| DNTH | $5.6B#12 | — | 4.8x#2 | 2753.9x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.9%#5 | — | — | 157.8%#9 | — |
| CYTK | $9.6B#5 | — | — | 109.6x#4 | 376.6%#1 | -33.2%#9 | -695.4%#4 | — | — | — | 46.0%#13 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice